Saltar al contenido
Merck

Inhibition of mucin glycosylation by aryl-N-acetyl-alpha-galactosaminides in human colon cancer cells.

The Journal of biological chemistry (1989-11-15)
S F Kuan, J C Byrd, C Basbaum, Y S Kim
RESUMEN

Specific inhibitors of the glycosylation of O-glycosidically linked glycoproteins have not previously been described. When tested for their effects on mucin glycosylation in a mucin-producing colon cancer cell line, LS174T, benzyl-, phenyl-, and p-nitrophenyl-N-acetyl-alpha-galactosaminide inhibited the formation of fully glycosylated mucin in a dose-dependent manner. Free aryl-oligosaccharides were found in the medium of treated cells labeled with [3H]glucosamine, [3H]galactose, [3H]fucose, [3H]mannosamine, or phenyl-alpha-[6-3H] N-acetylgalactosamine. UDP-Gal:GalNAc-beta 1,3-galactosyltransferase was inhibited by aryl-N-acetyl-alpha-galactosaminides but not by a number of other aryl-glycosides. Treatment with these inhibitors also causes reversible morphologic changes including formation of intercellular cysts. Aryl-N-acetyl-alpha-galactosaminides can be useful for the structural and functional studies of mucin macromolecules and other O-linked glycoproteins.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Benzyl 2-acetamido-2-deoxy-α-D-galactopyranoside hydrate, O-glycosylation inhibitor, ≥97% (TLC)
En este momento no podemos mostrarle ni los precios ni la disponibilidad